- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Treats Adults
Francesco Franchi, MD
Cardiologist
- Additional languages:
- Italian
(904) 383-1011
Request appointment online
Research at a glance
Top areas of exploration
- Platelet Aggregation Inhibitors , 83 publications
- Percutaneous Coronary Intervention , 49 publications
- Purinergic P2Y Receptor Antagonists , 43 publications
- Clopidogrel , 36 publications
Research activity
Active clinical trials
- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
My publications
Filter publications
143 publications
2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
European heart journal. Cardiovascular pharmacotherapy
鈥�2022
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
European heart journal. Cardiovascular pharmacotherapy
鈥�2022
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
European heart journal. Cardiovascular pharmacotherapy
鈥�2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.
Thrombosis and haemostasis
鈥�2022
Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Pharmacogenomics
鈥�